Clinical Data Data could move J&J’s Talvey earlier in myeloma therapy PharmaphorumJohnson Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.HematologyRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Johnson Johnson’s Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026. Hematology Read full story Post navigation Previous: FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatmentNext: Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
